SeaSpine Holdings

SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal hardware solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CARLSBAD, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Tuesday, August 2, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

SeaSpine to Report Second Quarter 2022 Financial Results on August 2, 2022

Provides for up to an additional $10 million of liquidity Provides for up to an additional $10 million of liquidity

SeaSpine Announces Three-Year Extension and Expansion of $30 Million Credit Facility

Agenus

Recursion Pharmaceuticals

Here's why we like SeaSpine, Recursion Pharmaceuticals, and Agenus.

3 Amazing Stocks Under $10

Company's second fully commercialized interbody system featuring the novel WaveForm 3D printed technology and that addresses an estimated $200 million cervical market opportunity Company's second fully commercialized interbody system featuring the novel WaveForm 3D printed technology and that addresses an estimated $200 million cervical market opportunity

SeaSpine® Announces Full Commercial Launch of WaveForm® C 3D-printed Interbody System

Company's first full commercial launch of novel 3D printed interbody product franchise that addresses estimated $500 million market opportunity Company's first full commercial launch of novel 3D printed interbody product franchise that addresses estimated $500 million market opportunity

SeaSpine Announces Full Commercial Launch of the WaveForm™ TO (TLIF Oblique) 3D-Printed Interbody System

iRhythm Technologies

Owlet

Here's why our roundtable likes iRhythm, SeaSpine Holdings, and Owlet.

3 Med-Tech Stocks With Incredible Potential

SeaSpine Holdings Corporation (NASDAQ:SPNE ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Leigh Salvo – Investor Relations Keith Valentine – Chief Executive Officer John Bostjancic – Chief Financial Officer Conference Call Participants Andrew Stafford – Piper Sandler Mathew Blackman – Stifel Jeffrey Cohen – Ladenburg Thalman Richard Newitter – Truist Jason Wittes – Loop Capital Ross Osborn – Cantor Fitzgerald Operator Welcome to the SeaSpine's 2022 First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode.

SeaSpine Holdings' (SPNE) CEO Keith Valentine on Q1 2022 Results - Earnings Call Transcript

SeaSpine (SPNE) delivered earnings and revenue surprises of -28.57% and 3.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine Holdings (SPNE) Reports Q1 Loss, Tops Revenue Estimates

CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the three-months ended March 31, 2022.

SeaSpine Reports 21 Percent Revenue Growth for First Quarter 2022 and Increases Full Year 2022 Revenue Guidance

CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team.

SeaSpine® Announces New Senior Leadership Team Appointments

CARLSBAD, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of OsteoTorrent and OsteoTorrent C, both of which are new Accell DBM Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate. The OsteoTorrent product families build on SeaSpine's Evo3®/OsteoSurge® 300 DBMs. The Company now offers both its best-of-class traditional DBM putties and DBM fibers packaged in a dry state.

SeaSpine® Announces Full Commercial Launch of OsteoTorrent™ DBM Product Families

SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will SeaSpine Holdings (SPNE) Report Negative Earnings Next Week? What You Should Know

SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?

CARLSBAD, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release first quarter financial results after the close of trading on Tuesday, May 3, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET.

SeaSpine to Report First Quarter 2022 Financial Results on May 3, 2022

CARLSBAD, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Reef TA (TLIF Articulating) Interbody System.

SeaSpine Announces Full Commercial Launch of the Reef® TA (TLIF Articulating) Interbody System

CARLSBAD, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the implantation of the 50,000th NanoMetalene® interbody device. NanoMetalene is a proprietary surface technology for interbody implants that incorporates a sub-micron layer of commercially pure titanium molecularly bonded to a PEEK implant using a high-energy, low-temperature process referred to as atomic fusion deposition. It is designed to provide a bone-friendly titanium surface with 360 degree coverage, while retaining the benefits associated with traditional PEEK implants, such as biocompatibility, a modulus of elasticity similar to bone, and excellent radiographic visibility for postoperative imaging.

SeaSpine® Announces 50,000th NanoMetalene® Implantation

CARLSBAD, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will participate in the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022 beginning at 2:30 pm ET.

SeaSpine to Participate in the Canaccord Musculoskeletal Conference

SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SeaSpine Holdings (SPNE) Reports Q4 Loss, Tops Revenue Estimates

Provides 2022 Revenue Guidance Provides 2022 Revenue Guidance

SeaSpine Announces Fourth Quarter and Full-Year 2021 Financial Results

Announces Date of Fourth Quarter and Full Year 2021 Financial Results Conference Call Announces Date of Fourth Quarter and Full Year 2021 Financial Results Conference Call

SeaSpine to Host Virtual Analyst and Investor Day on March 11, 2022

CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent.

SeaSpine Appoints Seasoned Healthcare Executive to its Board of Directors

SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.

SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System

CARLSBAD, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of its Admiral ACP System. Admiral ACP represents the next generation of anterior cervical plating and was designed to strike the optimal balance between strength, profile and construct rigidity. Differentiated plate features, combined with step-eliminating innovative instrumentation, work seamlessly in the surgeon's hands to create a more efficient and consistent anterior cervical discectomy and fusion (ACDF) experience.

SeaSpine Announces Full Commercial Launch of the Admiral™ ACP System

SeaSpine Holdings Corporation (SPNE) CEO Keith Valentine on Q3 2021 Results - Earnings Call Transcript

SeaSpine (SPNE) delivered earnings and revenue surprises of -54.84% and -3.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

News for SeaSpine Holdings Stock (SPNE)